You are here: » News » Newsdetails:

PolyActiva offers results of Phase IIa study of ocular implant

PolyActiva Pty Ltd. announced that the Phase IIa study of its PA5108 ocular implant for the treatment of primary open-angle glaucoma (POAG) met both the study's primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort.